Corcept Therapeutics Faces Securities Fraud Suit Following Class Period Volatility
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud during a critical 14-month period of operational and legal shifts. The Rosen Law Firm is seeking lead plaintiffs for a class period that concluded in late 2025, amid intensifying pressure on the company's core product patents.